ATE362468T1 - N-substituierte indole mit anwendung in der behandlung von diabetes - Google Patents

N-substituierte indole mit anwendung in der behandlung von diabetes

Info

Publication number
ATE362468T1
ATE362468T1 AT01954836T AT01954836T ATE362468T1 AT E362468 T1 ATE362468 T1 AT E362468T1 AT 01954836 T AT01954836 T AT 01954836T AT 01954836 T AT01954836 T AT 01954836T AT E362468 T1 ATE362468 T1 AT E362468T1
Authority
AT
Austria
Prior art keywords
treatment
substituted indoles
diabetes
application
agonists
Prior art date
Application number
AT01954836T
Other languages
German (de)
English (en)
Inventor
John Acton
Regina Marie Black
Anthony Brian Jones
Harold Blair Wood
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE362468T1 publication Critical patent/ATE362468T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT01954836T 2000-07-25 2001-07-20 N-substituierte indole mit anwendung in der behandlung von diabetes ATE362468T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22077800P 2000-07-25 2000-07-25

Publications (1)

Publication Number Publication Date
ATE362468T1 true ATE362468T1 (de) 2007-06-15

Family

ID=22824932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01954836T ATE362468T1 (de) 2000-07-25 2001-07-20 N-substituierte indole mit anwendung in der behandlung von diabetes

Country Status (8)

Country Link
US (1) US6525083B2 (https=)
EP (1) EP1305285B1 (https=)
JP (1) JP2004513076A (https=)
AT (1) ATE362468T1 (https=)
AU (2) AU2001277056B2 (https=)
CA (1) CA2415742A1 (https=)
DE (1) DE60128475T2 (https=)
WO (1) WO2002008188A1 (https=)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
HRP20030498A2 (en) * 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
DE60218165T2 (de) * 2001-05-28 2007-11-22 Kao Corp. Lipolyseförderer zur Reduzierung des Körpergewichts und medizinische Anwendung
US7025985B2 (en) * 2001-05-28 2006-04-11 Kanebo, Ltd. Dihydroxyphenyl compounds and glucoside compounds thereof
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
EP1435946B8 (en) 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2003088962A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
ITMI20021012A1 (it) * 2002-05-13 2003-11-13 Giovanni Scaramuzzino Combinazione di un inibitore dell'enzima hmg-coa reduttasi e di un estere nitrato
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
WO2004019869A2 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004020408A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
NZ537979A (en) 2002-09-12 2007-08-31 Hoffmann La Roche N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
DE10300099A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Indol-Phenylsulfonamid-Derivate
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
BRPI0409447A (pt) * 2003-04-14 2006-04-18 Inst For Pharm Discovery Inc ácidos fenilalcanóicos substituìdos
WO2004098510A2 (en) * 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
CN1812977A (zh) 2003-04-30 2006-08-02 药物研发有限责任公司 取代羧酸
WO2004100895A2 (en) * 2003-05-13 2004-11-25 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
WO2004110368A2 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
DE10335449A1 (de) * 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
DE10337839A1 (de) * 2003-08-18 2005-03-17 Bayer Healthcare Ag Indolin-Derivate
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
CN1875002B (zh) 2003-11-05 2011-08-03 霍夫曼-拉罗奇有限公司 作为ppar激动剂的苯基衍生物
RU2367659C2 (ru) 2003-11-05 2009-09-20 Ф.Хоффманн-Ля Рош Аг Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
EP1682507A1 (en) * 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Benzannelated compounds as ppar activators
CN1886133B (zh) 2003-12-04 2010-12-01 财团法人卫生研究院 吲哚化合物
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
EP1744747A4 (en) * 2004-04-26 2009-12-02 Univ Vanderbilt INDIC ACID AND INDULECTIC ACID DERIVATIVES AS THERAPEUTIC ACTIVITIES WITH REDUCED GASTROINTESTINAL TOXICITY
US20080076810A1 (en) * 2004-05-28 2008-03-27 Weiguo Lui Benzoureas Having Anti-Diabetic Activity
BRPI0511676A (pt) * 2004-05-29 2008-01-08 7Tm Pharma As uso medicinal de ligandos receptores
DE602005006806D1 (de) * 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
EP1765329A2 (en) 2004-07-02 2007-03-28 Merck & Co., Inc. Indoles having anti-diabetic activity
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
AU2005266337A1 (en) 2004-07-30 2006-02-02 Laboratorios Salvat, S.A. Tyrosine derivatives as PPAR-gamma-modulators
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
AU2005307718A1 (en) * 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids for the treatment of diabetes
WO2006063132A2 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
FR2880887B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
CN101128441A (zh) 2005-03-04 2008-02-20 默克公司 具有抗糖尿病活性的稠合芳香化合物
KR20080007491A (ko) * 2005-04-29 2008-01-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ES2375302T3 (es) * 2005-05-24 2012-02-28 Dsm Ip Assets B.V. Derivados de ligustilida para el tratamiento de trastornos inflamatorios.
AU2006269503A1 (en) 2005-07-06 2007-01-18 Merck & Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
JP2009502923A (ja) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
US20070161006A1 (en) * 2006-01-10 2007-07-12 Vita Genomics, Inc. Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma
SG10201404220TA (en) * 2006-04-11 2014-10-30 Arena Pharm Inc Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7736624B2 (en) 2006-06-19 2010-06-15 Univ Vanderbilt Methods and compositions for diagnostic and therapeutic targeting of COX-2
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
KR101568799B1 (ko) 2007-01-26 2015-11-12 카네크 파마 인코포레이티드 융합된 방향족 ｐｔｐ-1ｂ 억제제
JP5301469B2 (ja) * 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
US8338458B2 (en) 2007-05-07 2012-12-25 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
FR2921366B1 (fr) * 2007-09-26 2009-12-04 Servier Lab Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
EP2108960A1 (en) * 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
AU2010206789A1 (en) 2009-01-23 2011-07-28 Merck Sharp & Dohme Corp. Bridged and fused antidiabetic compounds
WO2010085525A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
AR075051A1 (es) 2009-02-05 2011-03-02 Schering Corp Compuestos antidiabeticos que contienen ftalazina
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2464228B1 (en) 2009-08-13 2017-12-06 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
CA2771352A1 (en) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN102695414A (zh) 2010-01-15 2012-09-26 默沙东公司 作为抗糖尿病化合物的噁二唑β-咔啉衍生物
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US8742110B2 (en) 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9108920B2 (en) 2010-10-29 2015-08-18 Merck Sharp & Dohme Corp. Diazeniumdiolate heterocyclic derivatives
RU2598842C2 (ru) 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
WO2012138845A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US9272987B2 (en) 2011-05-02 2016-03-01 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives
US20140088124A1 (en) 2011-06-02 2014-03-27 Robert J. DeVita Imidazole derivatives
US9006228B2 (en) 2011-06-16 2015-04-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2012178142A1 (en) * 2011-06-23 2012-12-27 Metabolic Solutions Development Company, Llc Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
US9422266B2 (en) 2011-09-30 2016-08-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2765859B1 (en) 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
WO2013068328A1 (en) 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013068439A1 (en) 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
AU2012339870B2 (en) 2011-11-15 2017-06-29 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2013155600A1 (en) 2012-04-16 2013-10-24 Kaneq Pharma Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
EP2874622A4 (en) 2012-07-23 2015-12-30 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
EP2931734B1 (en) 2012-12-17 2020-12-02 Merck Sharp & Dohme Corp. Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
US9717714B2 (en) 2012-12-19 2017-08-01 Merck Sharp & Dohme Corp. Spirocyclic CETP inhibitors
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
WO2015112465A1 (en) 2014-01-24 2015-07-30 Merck Sharp & Dohme Corp. Isoquinoline derivatives as mgat2 inhibitors
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016018729A1 (en) 2014-07-29 2016-02-04 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
MX383117B (es) 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CR20170164A (es) 2014-10-24 2017-08-29 Merck Sharp & Dohme Coagonistas de los receptores de glucagón y de glp-1
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3303342B1 (en) 2015-05-27 2021-03-17 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
EP3322420B1 (en) 2015-07-13 2021-12-29 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
EP3359191A4 (en) 2015-10-05 2019-05-29 Merck Sharp & Dohme Corp. ANTIBODY PEPTIDE CONJUGATES WITH AGONISTEACTIVITY ON GLUCAGON RECEPTORS AND GLUCAGON-LIKE PEPTIDE-1
WO2017095724A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
EP3383869B1 (en) 2015-11-30 2023-06-28 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
EP3496715B1 (en) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
WO2018034918A1 (en) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
US11008313B2 (en) 2016-09-20 2021-05-18 Merck Sharp & Dohme Corp. Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders
AU2017360939B2 (en) 2016-11-18 2022-03-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
WO2018093698A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2018107415A1 (en) 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. Hydroxy isoxazole compounds useful as gpr120 agonists
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
US12281109B2 (en) 2019-04-04 2025-04-22 Merck Sharp & Dohme Llc Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
EP3972589B1 (en) 2019-05-22 2024-07-03 Merck Sharp & Dohme LLC Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
WO2020236688A1 (en) 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
EP4021919A1 (en) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
EP3842060A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP4153584A1 (en) 2020-05-18 2023-03-29 Merck Sharp & Dohme LLC Novel diacylglyceride o-acyltransferase 2 inhibitors
EP4225735A1 (en) 2020-10-08 2023-08-16 Merck Sharp & Dohme LLC Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
WO2023023245A1 (en) 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Compounds for treating conditions related to pcsk9 activity
CN119866342A (zh) 2022-06-15 2025-04-22 默沙东有限责任公司 用于捕获白介素-1β的环肽
AR131250A1 (es) 2022-12-02 2025-02-26 Merck Sharp & Dohme Llc Preparación de derivados condensados de azol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
US20250152658A1 (en) 2023-11-14 2025-05-15 Merck Sharp & Dohme Llc Cyclic peptide for trapping interleukin-1 beta
TW202542176A (zh) 2023-12-15 2025-11-01 美商默沙東有限責任公司 用於治療動脈粥樣硬化及發炎病症之環狀肽IL-1β捕捉劑
WO2026019977A1 (en) 2024-07-19 2026-01-22 Merck Sharp & Dohme Llc Pyrrolopyridazine vegfr inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3564009A (en) 1966-01-13 1971-02-16 Sumitomo Chemical Co Process for producing 1-acylindole derivatives
CH605744A5 (https=) 1973-11-29 1978-10-13 Crc Ricerca Chim
JPH04501722A (ja) 1988-11-14 1992-03-26 ジ・アップジョン・カンパニー 抗―糖尿病、抗―肥満症および抗―アテローム性動脈硬化症薬として有用なα―アミノ―インドール―３―酢酸
JPH0764841B2 (ja) 1990-10-03 1995-07-12 ファイザー製薬株式会社 インドール誘導体およびその用途
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
FI944602A0 (fi) 1992-04-03 1994-10-03 Upjohn Co Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit
ZA939516B (en) * 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
US5686481A (en) * 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
EP0773942A1 (en) 1994-07-26 1997-05-21 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
MX9700696A (es) 1994-07-27 1997-04-30 Sankyo Co Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
EP0768311B1 (en) * 1995-03-09 2003-08-06 Kyowa Hakko Kogyo Co., Ltd. Pyrrolocarbazole derivatives
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
EP0922028A1 (en) 1996-08-26 1999-06-16 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
EP1062216A1 (en) 1998-02-25 2000-12-27 Genetics Institute, Inc. Inhibitors of phospholipase a2
EE200000486A (et) 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal
EE200000488A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
WO2000035886A2 (en) * 1998-12-18 2000-06-22 Axys Pharmaceuticals, Inc. (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors

Also Published As

Publication number Publication date
US6525083B2 (en) 2003-02-25
AU2001277056B2 (en) 2005-09-29
DE60128475D1 (de) 2007-06-28
AU7705601A (en) 2002-02-05
CA2415742A1 (en) 2002-01-31
US20020042441A1 (en) 2002-04-11
EP1305285A1 (en) 2003-05-02
DE60128475T2 (de) 2008-02-07
EP1305285A4 (en) 2005-08-03
EP1305285B1 (en) 2007-05-16
WO2002008188A1 (en) 2002-01-31
JP2004513076A (ja) 2004-04-30

Similar Documents

Publication Publication Date Title
ATE362468T1 (de) N-substituierte indole mit anwendung in der behandlung von diabetes
ATE333448T1 (de) Arylthiazolidinedione und aryloxa zolidinedion- derivate
WO2002026729A3 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
WO2002064094A3 (en) 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
WO2002060434A3 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
WO2002060388A3 (en) Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
WO2004066963A3 (en) N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
EP1040102A4 (en) ARYLTHIAZOLIDINDION DERIVATIVES
CA2495943A1 (en) Indoles having anti-diabetic activity
ATE307798T1 (de) Glucagon antagonisten/inverse agonisten
NO20075000L (no) Kondenserte aromatiske forbindelser med anti-diabetisk aktivitet
DK0699192T3 (da) Substituerede oxazolylforbindelser til behandling af inflammation
FI964314A0 (fi) Substituoidut sulfonamidit selektiivisinä beta3-agonisteina diabeteksen ja liikalihavuuden hoitoon
EA200401153A1 (ru) Соединения, модулирующие активность ppar, и способы их получения
DK0714386T3 (da) Vandopløseligt nimesulidsalt og anvendelse deraf til behandling af inflammatoriske lidelser
DK1267869T3 (da) Metabotrope glutamatreceptorantagonister til behandling af tolerance og afhængighed
HRP20080467A2 (hr) Derivati 5-beta-sapogenina i pseudosapogenina te njihova uporaba u liječenju demencije
ES2345882T3 (es) Nuevos compuestos y su uso como moduladores de ppar.
DE602005001265D1 (de) Antidiabetische oxazolidindione und thiazolidindione
AU7127096A (en) Substituted 2-phenylpyridines as herbicides
MY139550A (en) Indoles having anti-diabetic activity
DOP2003000770A (es) Indoles con actividad antibiabetica
WO2006022954A3 (en) Benzoureas having anti-diabetic activity
FI963785A0 (fi) Hypokolesteroleemisia, antiateroskleroottisia ja hypotriglyserideemisiä merkaptoasetyyliamidijohdannaisia
NO963988D0 (no) Hypokolesterolemiske-, antiatherosklerotiske-, og hypotriglyceridemiske mercaptoacetylamidderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties